Replies to post #202595 on Biotech Values

[biomaven0]

I think it's just the FDA being cautious as they roll out the biosimilar program - give experts the chance to raise questions the FDA might not have publicly discussed.

I assume that after a while they will drop the panels for all or most applications.

Peter

[xavierprivas]

I agree with it. MNTA has several biosimilars and the path to approval is
a lot easier now.

[DewDiligence]

FDA panel votes 20-0 for NVS’ Enbrel FoB. (No link yet.)